Seagen’s Bladder Cancer Trial Data Meets Expectation, Analysts Say
Earlier today, Seagen Inc (NASDAQ:FBI) and Astellas Pharma Inc (OTC:ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev…
Aurinia Pharmaceuticals Receives Notice Regarding USPTO Trial And Appeal Board Decision To Institute Trial On Inter Partes Review Filed By Sun Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) has reported results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development…
Virax Biolabs Introduces Monkeypox And Varicella-Zoster Viruses Real-Time PCR Detection Kit
Virax Biolabs Group Limited (“Virax” or the “Company”) (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched
Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol
- ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023
Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)
Unicycive Reports Findings from Independent Renal Dietitian Survey
Hyperphosphatemia ranked as area of greatest unmet need
Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden
Confirms patient preference for pills that are swallowed vs
Bausch + Lomb Enrolls First Patient In LASIK Clinical Trial Evaluating Use Of Technolas TENEO™ Excimer Laser For Vision Correction Surgery for Hyperopia with Astigmatism
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient